# US Genetic Engineering Market > US Genetic Engineering Market Research Report By Product (Biochemical, Genetic Markers), By Devices (PCR, Gene Gun, Gel Assemblies), By Technique (Artificial Selection, Gene Splicing) and By Application (Agriculture, Medical Industry) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 20.02% - **2024:** $ 268.8 Million - **2025:** $ 322.61 Million - **2035:** $ 2,000 Million - **Key Players:** Monsanto (US), Syngenta (CH), Bayer (DE), DuPont (US), Amgen (US), Genentech (US), Regeneron Pharmaceuticals (US), Corteva (US) **Report ID:** MRFR/LS/17825-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** July 29, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-genetic-engineering-market-19372 --- ## Market Summary ## **US Genetic Engineering Market Overview** As per MRFR analysis, the US Genetic Engineering Market Size was estimated at 380.8 (USD Million) in 2023. The US Genetic Engineering Market Industry is expected to grow from 500(USD Million) in 2024 to 4,050 (USD Million) by 2035. The US Genetic Engineering Market CAGR (growth rate) is expected to be around 20.945% during the forecast period (2025 - 2035). ### **Key US Genetic Engineering Market Trends Highlighted** In the US Genetic Engineering Market, key market drivers are pushing the field forward as innovations continue to evolve. Federal policies supporting biotechnology, such as the Coordinated Framework for the Regulation of Biotechnology, provide a structured pathway for genetically engineered products, encouraging both research and commercialization. Enhanced funding from initiatives like the National Institutes of Health (NIH) and the United States Department of Agriculture (USDA) has also played a significant role in driving advancements in genetic engineering technologies. Opportunities abound in areas such as agriculture, where genetically modified organisms (GMOs) offer prospective solutions to food security issues and sustainability challenges.Additionally, there is a growing interest in gene therapies and precision medicine, providing a fertile ground for developing targeted treatments for various genetic disorders.  Trends in recent times reveal a notable shift towards public acceptance and ethical considerations surrounding genetic engineering applications. The US population shows increasing curiosity and support for biotechnology that promises safe food systems and health benefits. Moreover, advancements in CRISPR technology and gene editing are capturing significant attention, allowing for precise modifications in organisms, which could lead to enhanced crop yields and disease resistance.Regulatory bodies are gradually adapting to these changes, seeking to balance innovation with safety and ethical guidelines. The rise of plant-based and lab-grown food products is also influencing the market, pushing for integrated approaches that utilize genetic engineering within sustainable models. Continuous research and advocacy are shaping the landscape, leading to a more informed dialogue between scientists, policymakers, and the public. Thus, the US Genetic Engineering Market stands at the crossroads of rapid advancements and emerging societal implications. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Genetic Engineering Market Drivers** ### **Increase in Genetic Disorders and Diseases** The rising incidence of genetic disorders and diseases in the United States is expected to significantly drive growth in the US Genetic Engineering Market Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 33 babies is born with a genetic disorder, indicating a growing patient population requiring innovative solutions such as genetic engineering. Furthermore, as healthcare technologies evolve, there is a strong demand for advanced therapeutic techniques including genomic medicine and gene therapy.Major organizations such as the National Institutes of Health (NIH) and the American Society of Human Genetics (ASHG) are actively supporting research and initiatives aimed at understanding and treating genetic conditions, further driving investment and interest in the genetic engineering sector. The potential for genetic engineering to offer targeted treatments and potentially curative therapies also enhances its appeal, prompting increased funding and collaboration across research institutions and biotechnology firms. ### **Advancements in Technology** The US Genetic Engineering Market Industry is propelled by significant advancements in genetic engineering technologies such as CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats). The growing availability and capability of gene-editing technologies are simplifying the modification of genetic material, making it more accessible for various applications. As reported by the National Science Foundation, funding for biotechnology research and development in the US has seen a substantial increase, which supports innovation in genetic engineering techniques.Institutions such as Stanford University and MIT are at the forefront of developing these technologies, thus influencing the market dynamics through advancements that reduce the time and costs associated with genetic engineering processes. This creates ample opportunities for companies to innovate and market products in the genetic engineering space. ### **Government Support and Regulation** Government policies and regulations play a pivotal role in shaping the US Genetic Engineering Market Industry. The United States government has shown a strong commitment to supporting biotechnological advancement through grants and legislative initiatives aimed at fostering innovative research. For instance, the Executive Order on Advancing Biotechnology and Biomanufacturing outlines significant federal investment aimed at ensuring the US maintains its leadership in biotechnology innovation.This proactive approach by federal agencies such as the Food and Drug Administration (FDA) and the Department of Agriculture (USDA) has led to streamlined regulatory pathways, encouraging companies to invest in genetic engineering solutions that could address pressing health issues and food security challenges faced by the nation. ### **Rising Demand for Genetically Modified Crops** The growing need for sustainable agricultural practices is driving demand for genetically modified crops in the US Genetic Engineering Market Industry. According to the United States Department of Agriculture (USDA), the adoption of genetically engineered crops has enabled farmers to increase yield while minimizing pesticide use and reducing environmental impact. With food security becoming an increasing concern amidst population growth, the use of genetically engineered crops presents solutions that enhance food production efficiency.Organizations like the American Farm Bureau Federation are advocating for the benefits of genetic engineering in agriculture by promoting policies that encourage the use of biotechnology in farming, thus enhancing adoption rates and driving market growth. ## **US Genetic Engineering Market Segment Insights** ### **Genetic Engineering Market Product Insights** The US Genetic Engineering Market is exhibiting substantial growth driven by advancements in biotechnology and genetics, particularly in the Product segment. Within this segment, Biochemical and Genetic Markers are gaining traction due to their crucial applications in various industries including healthcare, agriculture, and research. The utilization of Biochemicals in genetic engineering allows for the development of innovative therapies and diagnostics, playing a pivotal role in precision medicine. As the focus on personalized healthcare continues to rise, Biochemicals are proving essential in creating targeted treatments that cater to individual genetic profiles. This trend is reflected in the increasing demand for biopharmaceuticals and the development of novel drugs, as they harness the power of genetic engineering to enhance efficacy and reduce side effects. Meanwhile, Genetic Markers are significant in facilitating advancements in genetic research and forensics, as they help identify specific traits or predispositions to diseases in various organisms.  Their application is substantial in crop improvement, allowing for the development of genetically modified organisms that can withstand environmental stresses and disease, boosting food security. Moreover, the evolving landscape of genomic data analysis emphasizes the need for accurate and reliable Genetic Markers, contributing to significant advancements in both medical diagnostics and agricultural biotechnology. This growing emphasis on genetic innovation aligns with nationwide initiatives aimed at enhancing health outcomes and agricultural efficiency, reinforcing the importance of these components in the overall US Genetic Engineering Market data.  The robust growth of this market segment is supported by ongoing Research and Development activities, which are likely to continue shaping the future of genetic engineering and its expansive market segmentation. The implications of these advancements stretch far beyond the laboratory, influencing both policy and public health markers, demonstrating the integral role that these particular elements of the Product segment play in the overarching US Genetic Engineering Market industry. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Genetic Engineering Market Devices Insights** The Devices segment of the US Genetic Engineering Market plays a crucial role in the advancement of biotechnological applications, as it encompasses essential tools such as PCR (Polymerase Chain Reaction), Gene Guns, and Gel Assemblies. PCR stands out for its ability to amplify DNA, making it indispensable in various fields including Research and Development, diagnostics, and forensic science, significantly driving the market growth. The Gene Gun, another notable technology, is pivotal in gene transfer processes, particularly in plant genetics, facilitating the creation of genetically modified organisms that address agricultural challenges.Gel Assemblies are vital for visualizing and analyzing DNA and RNA samples, serving as a foundational technique in molecular biology labs. With a robust supporting framework from regulatory bodies, coupled with increasing investments in Research and Development, the Devices segment is set to enhance the efficiency and accuracy of genetic engineering processes. The focus on these technologies reflects the industry's commitment to innovation and meets the rising demand for advanced genetic manipulation methods in the US market. ### **Genetic Engineering Market Technique Insights** The Technique segment of the US Genetic Engineering Market showcases innovative methodologies driving advancements in the field, particularly focusing on Artificial Selection and Gene Splicing. Artificial Selection has remained a fundamental practice, allowing the manipulation of traits in organisms to enhance desirable characteristics. This technique plays a critical role in agriculture, contributing significantly to crop yield improvement and disease resistance, aligning with the increasing demand for sustainable food production in the US. Gene Splicing, on the other hand, offers the ability to directly alter an organism's genetic material, paving the way for groundbreaking treatments in medicine, including gene therapies for genetic disorders. As research in Genetic Engineering progresses, these techniques are becoming increasingly significant, responding to the challenges of food security and health care. The current trends showcase a surge in investments targeted towards these methodologies, driven by the potential for large-scale applications and effective solutions to critical societal challenges. With robust support from government initiatives, these segments are poised to dominate the US Genetic Engineering Market, reflecting a strong alignment with the shifting priorities in health and agricultural sectors. ### **Genetic Engineering Market Application Insights** The Application segment of the US Genetic Engineering Market is a critical area driving innovation and development across various sectors. The Agriculture sector leverages genetic engineering to enhance crop resilience, yield, and nutritional value, thereby addressing food security challenges and adapting to climate change. This segment plays a significant role in developing genetically modified organisms (GMOs) that are crucial for modern agricultural practices. In the Medical Industry, genetic engineering facilitates advancements in [gene therapy](../../../reports/gene-therapy-market-8399), personalized medicine, and biopharmaceuticals, significantly improving patient outcomes and treatment efficacy. The US Genetic Engineering Market segmentation highlights the importance of these applications as they pave the way for revolutionary breakthroughs in healthcare and sustainable farming practices. Key growth drivers for this market include increasing demand for food due to population growth, stringent regulations promoting advanced biotechnologies, and rising investment in research and development initiatives. However, challenges such as regulatory hurdles and public perception of genetically engineered products remain prevalent. Nonetheless, the continuous evolution of genetic engineering tools presents ample opportunities for further innovation, making these applications vital for future advancements in both agriculture and medicine. ## **US Genetic Engineering Market Key Players and Competitive Insights** The US Genetic Engineering Market is characterized by a dynamic landscape where technological advancements and innovation spur competition among a diverse range of companies. As genetic engineering continues to evolve, organizations within this sector strive to maintain or enhance their market position through research and development, strategic partnerships, and product diversification. The competitive insights reveal a market driven by a mix of established players and emerging startups, all vying to leverage genetic technologies for applications that range from agriculture to healthcare. The rapid pace of advancements in gene editing technologies, including CRISPR and genome sequencing, has intensified competition, compelling companies to invest heavily in new methodologies and solutions that can address the ever-increasing demand for personalized medicine and agricultural efficiency. Illumina stands as a prominent player in the US Genetic Engineering Market, recognized for its innovative sequencing technologies and contributions to genomics research. The company has established a solid market presence through its advanced sequencing platforms, which have become integral to both clinical applications and scientific research. Illumina's strengths lie in its ability to continuously evolve its product offerings, ensuring they remain at the forefront of genomic discovery and precision medicine. This commitment to innovation is supported by significant investments in research and collaboration with academic institutions and healthcare organizations, allowing Illumina to maintain leadership in developing tools that facilitate comprehensive genomic analysis. Genentech, another key entity in the US Genetic Engineering Market, is known for its pioneering role in biotechnology and the therapeutic applications of genetic engineering. The company boasts a robust portfolio of biologic therapies that focuses on areas such as cancer, immunology, and neuroscience, driven by a strong commitment to research and development. Genentech's market presence is strengthened by its strategic mergers and acquisitions, which have augmented its capabilities in genetic engineering and expanded its product line. The company's strengths include its rich pipeline of innovative treatments, a solid reputation for quality among its peers, and an ongoing dedication to delivering breakthrough therapies that enhance patient outcomes. By integrating advanced genetic technologies into its research and production processes, Genentech continues to solidify its position as a leader in the competitive landscape of genetic engineering within the US. ### **Key Companies in the US Genetic Engineering Market Include** ### **US Genetic Engineering Market Industry Developments** The US Genetic Engineering Market has seen significant activity recently, especially with companies such as Illumina, Genentech, Zymeworks, and Editas Medicine making strides in Research and Development. In October 2023, Editas Medicine announced a collaboration with a major pharmaceutical company to enhance its gene-editing technologies. Additionally, Genentech reported advancements in its portfolio targeting genetic therapies for rare diseases. The growing investment in CRISPR technology has been underscored by CRISPR Therapeutics engaging in further development initiatives, projected to positively impact the market valuation, which has been estimated to reach over $70 billion by 2025. In August 2022, Thermo Fisher Scientific acquired the assets of a leading gene synthesis firm, boosting its capabilities in genetic analysis. Monsanto and Corteva are also expanding their gene editing techniques in agricultural biotechnology, reflecting a growing trend to enhance crop resistance. The US Genetic Engineering Market is marked by innovation and collaboration among major players as they seek to address biotechnology challenges while maintaining regulatory compliance from bodies like the Food and Drug Administration. ## **US Genetic Engineering Market Segmentation Insights** ### **Genetic Engineering Market Product Outlook** ### **Genetic Engineering Market Devices Outlook** ### **Genetic Engineering Market Technique Outlook** ### **Genetic Engineering Market Application Outlook** ## Market Drivers ### Emerging Regulatory Frameworks The genetic engineering market is influenced by the evolving regulatory frameworks that govern biotechnology. In the US, agencies such as the FDA and USDA are actively developing guidelines to ensure the safety and efficacy of genetically engineered products. These regulations are crucial for fostering public trust and acceptance of genetic engineering technologies. As the regulatory landscape becomes clearer, companies in the genetic engineering market may find it easier to navigate compliance, potentially accelerating product development timelines. The establishment of robust regulatory frameworks is likely to enhance innovation and investment in the genetic engineering market. ### Rising Investment in Biotechnology The genetic engineering market is experiencing a surge in investment, particularly from venture capital and private equity firms. In recent years, funding for biotechnology startups has increased significantly, with estimates suggesting that investments reached approximately $20 billion in 2024. This influx of capital is likely to accelerate research and development activities, leading to innovative solutions in genetic engineering. The focus on developing therapies for genetic disorders and enhancing agricultural productivity is driving this trend. As investors recognize the potential for high returns in the genetic engineering market, the financial backing is expected to foster advancements in technology and product development, ultimately benefiting the industry as a whole. ### Expanding Applications in Agriculture The genetic engineering market is expanding its applications in agriculture, particularly in the development of genetically modified organisms (GMOs) that enhance crop yield and resistance to pests. With the global population projected to reach 9 billion by 2050, the demand for food is expected to increase significantly. The market for agricultural biotechnology is anticipated to grow by approximately 15% annually, driven by the need for sustainable farming practices. Genetic engineering offers solutions to improve food security and reduce the environmental impact of agriculture. As farmers and agricultural companies adopt these technologies, the genetic engineering market is likely to see substantial growth. ### Growing Public Awareness and Acceptance The genetic engineering market is experiencing a shift in public perception, with increasing awareness and acceptance of biotechnology applications. Educational initiatives and outreach programs are helping to inform the public about the benefits of genetic engineering, particularly in healthcare and agriculture. Surveys indicate that approximately 60% of the population now supports the use of genetic engineering for food production, reflecting a growing understanding of its potential advantages. This shift in public sentiment is likely to create a more favorable environment for the genetic engineering market, encouraging investment and innovation as stakeholders recognize the value of these technologies. ### Increased Focus on Personalized Medicine The genetic engineering market is witnessing a notable shift towards personalized medicine, which tailors medical treatment to individual characteristics. This trend is driven by advancements in genomic sequencing technologies, which have become more accessible and affordable. As a result, healthcare providers are increasingly utilizing genetic information to inform treatment decisions, particularly in oncology and rare diseases. The market for personalized medicine is projected to grow at a CAGR of around 10% through 2026, indicating a robust demand for genetic engineering solutions. This focus on individualized therapies is likely to enhance patient outcomes and drive further investment in the genetic engineering market. ## Future Outlook The [Genetic Engineering Market](https://www.marketresearchfuture.com/reports/genetic-engineering-market-1528) is projected to grow at a 20.02% CAGR from 2025 to 2035, driven by advancements in biotechnology, regulatory support, and increasing demand for sustainable solutions. **New opportunities:** - Development of CRISPR-based therapeutics for rare diseases. - Expansion of genetically modified crops to enhance food security. - Investment in synthetic biology for biofuel production. By 2035, the genetic engineering market is expected to achieve substantial growth, driven by innovation and strategic investments. ## Segment Insights ### By Product: Biochemical (Largest) vs. Genetic Markers (Fastest-Growing) In the US genetic engineering market, the Biochemical segment holds the largest market share, driven by its established applications in pharmaceuticals and agricultural biotechnology. With a well-established infrastructure and a strong research base, Biochemical continues to dominate, reflecting the industry's reliance on traditional methodologies and processes. On the other hand, Genetic Markers are emerging rapidly as a key player in the US genetic engineering landscape. Their growth is propelled by advancements in personalized medicine and diagnostics, as well as increased investment in genomic research. As technologies evolve, the demand for Genetic Markers is expected to surge, further shifting the competitive dynamics in this sector. Biochemical (Dominant) vs. Genetic Markers (Emerging) Biochemical is characterized by its extensive use in drug development, vaccine production, and agriculture, making it a cornerstone of the genetic engineering sector. Its dominance is underscored by robust R&D activities and regulatory support, which have fostered innovation and stability within this segment. Conversely, Genetic Markers represent a burgeoning opportunity, focusing on the development of genetic tests and profiling technologies that cater to personalized healthcare solutions. As the world increasingly embraces tailored treatments, Genetic Markers are positioned to capitalize on this shift, bolstered by ongoing research and consumer demand for precision medicine. ### By Devices: PCR (Largest) vs. Gene Gun (Fastest-Growing) The US genetic engineering market has seen notable diversity among its devices segment, with PCR technologies leading the charge. Currently, PCR holds a significant market share due to its widespread application in diagnostics, research, and various biotechnological processes. In contrast, while the Gene Gun has a smaller share, it is rapidly gaining traction as researchers seek efficient methods for gene delivery into plant and animal cells. Growth trends in this segment indicate a robust trajectory for both PCR and Gene Gun technologies. Increasing investments in genetic research and biotechnology innovations are crucial drivers behind this growth. Additionally, the demand for advanced genetic tools among academic institutions and pharmaceutical companies is elevating the importance of these devices, with Gel Assemblies also contributing to strategic advancements in gene editing techniques. PCR (Dominant) vs. Gel Assemblies (Emerging) PCR stands as the dominant technology in the devices segment, recognized for its precision and efficiency in amplifying DNA samples. It is extensively utilized in laboratories for genetic testing, disease diagnosis, and forensic applications. On the other hand, Gel Assemblies are emerging, offering innovative solutions in gene assembly and molecular cloning. These tools are gaining popularity due to their ability to facilitate complex genetic modifications and streamline workflows in research settings. While PCR is established as a staple in the market, Gel Assemblies are being increasingly adopted, highlighting a shift towards more versatile and integrated genetic engineering solutions. ### By Technique: Gene Splicing (Largest) vs. Artificial Selection (Fastest-Growing) In the US genetic engineering market, Gene Splicing holds a substantial market share due to its advanced capabilities in creating precise genetic modifications. This method allows for the incorporation of specific traits from one organism into another, resulting in enhanced characteristics and higher yields. In contrast, Artificial Selection, while traditional, has seen a resurgence as consumers increasingly favor naturally derived products. Market share is leaning towards Gene Splicing as it offers significant advantages in crop resilience and product quality. Growth trends indicate a robust demand for Gene Splicing technologies, driven by the need for increased agricultural productivity and sustainability. Innovations in this domain are frequent, offering new solutions to food security challenges. Artificial Selection is gaining traction as an emerging method, supported by consumer preferences for organic and heritage varieties. As awareness of genetic engineering increases, both techniques will play pivotal roles in shaping the future of biotechnology in agriculture. Gene Splicing (Dominant) vs. Artificial Selection (Emerging) Gene Splicing is characterized by its precision and ability to directly manipulate genetic material, making it the dominant technique in the US genetic engineering market. This method allows for the introduction of specific genes, enabling the development of crops with desirable traits such as pest resistance and improved nutritional profiles. On the other hand, Artificial Selection has emerged as a popular method due to its appeal among consumers who prioritize organic and traditional approaches to farming. While it relies on breeding methods, recent advancements have revitalized interest, creating opportunities for niche markets focused on heritage crops and natural genetics. Both techniques contribute to a diverse product landscape within the market. ### By Application: Agriculture (Largest) vs. Medical Industry (Fastest-Growing) In the US genetic engineering market, the application segment is primarily dominated by agriculture, which commands a significant portion of market share. This sector includes biotechnological advancements in crops, focusing on increasing yield, disease resistance, and pest management. Meanwhile, the medical industry is gaining traction, particularly in gene therapy and personalized medicine, capturing a smaller yet rapidly expanding share of the market. Growth trends in the application segment are propelled by increasing investments in research and development within the agricultural field and a rising demand for genetically modified organisms (GMOs). In contrast, the medical industry benefits from advancements in genetic research and technology, leading to innovative therapies and treatments. Both segments are expected to see substantial growth, but medical applications are emerging as a key driver of future market dynamics. Agriculture: Dominant vs. Medical Industry: Emerging Agriculture is the dominant segment in the application category of the US genetic engineering market, given its critical role in enhancing food security and sustainability through genetic modifications. This segment focuses on developing crops that can thrive under adverse environmental conditions and possess traits that improve overall productivity. On the other hand, the medical industry is an emerging segment, characterized by its focus on groundbreaking therapies such as CRISPR and gene editing technologies aimed at treating genetic disorders. The interplay between these segments illustrates a dynamic landscape where agriculture holds a substantial market share, while the medical industry is swiftly gaining momentum due to technological advancements and increasing healthcare demands. ## Competitive Benchmarking The genetic engineering market is characterized by a dynamic competitive landscape, driven by rapid advancements in biotechnology and increasing demand for genetically modified organisms (GMOs) across various sectors, including agriculture and pharmaceuticals. Key players such as Monsanto (US), Bayer (DE), and Amgen (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Monsanto (US) focuses on innovation in crop biotechnology, emphasizing the development of drought-resistant and pest-resistant seeds, which aligns with the growing need for sustainable agricultural practices. Bayer (DE), on the other hand, has been actively pursuing mergers and acquisitions to expand its portfolio, thereby enhancing its capabilities in genetic engineering and crop protection. Amgen (US) is leveraging its expertise in biopharmaceuticals to explore gene therapies, indicating a shift towards personalized medicine, which is becoming increasingly relevant in the healthcare sector. Collectively, these strategies contribute to a competitive environment that is both concentrated and evolving, as companies seek to differentiate themselves through technological advancements and strategic partnerships.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several key players exerting significant influence. This fragmentation allows for a variety of innovations and approaches, fostering a competitive atmosphere where companies must continuously adapt to maintain their market share. The collective influence of these major players shapes the market dynamics, as they engage in strategic collaborations and investments to bolster their competitive edge. In October Corteva (US) announced a partnership with a leading agricultural technology firm to develop advanced gene-editing tools aimed at improving crop yields. This strategic move underscores Corteva's commitment to innovation and its focus on addressing the challenges posed by climate change and food security. By leveraging cutting-edge technology, Corteva positions itself as a leader in sustainable agriculture, potentially reshaping the competitive landscape in the sector. In September Regeneron Pharmaceuticals (US) launched a new gene therapy aimed at treating a rare genetic disorder, marking a significant advancement in its biopharmaceutical offerings. This initiative not only highlights Regeneron's dedication to addressing unmet medical needs but also reflects the growing trend of integrating genetic engineering into therapeutic solutions. The successful implementation of this therapy could enhance Regeneron's reputation and market position in the rapidly evolving field of gene therapy. In August Syngenta (CH) expanded its research and development facilities in the US, focusing on the development of genetically modified crops that are resistant to emerging pests and diseases. This expansion indicates Syngenta's proactive approach to maintaining its competitive edge in the agricultural sector, as it seeks to provide farmers with innovative solutions that enhance productivity and sustainability. The investment in R&D is likely to yield long-term benefits, reinforcing Syngenta's market presence. As of November current trends in the genetic engineering market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in research and development processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and addressing complex challenges. Looking ahead, competitive differentiation is expected to evolve, with a notable shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine the competitive landscape, as companies that prioritize these elements are likely to emerge as leaders in the genetic engineering market. ## Recent News & Developments The US Genetic Engineering Market has seen significant activity recently, especially with companies such as Illumina, Genentech, Zymeworks, and Editas Medicine making strides in Research and Development. In October 2023, Editas Medicine announced a collaboration with a major pharmaceutical company to enhance its gene-editing technologies. Additionally, Genentech reported advancements in its portfolio targeting genetic therapies for rare diseases. The growing investment in CRISPR technology has been underscored by CRISPR Therapeutics engaging in further development initiatives, projected to positively impact the market valuation, which has been estimated to reach over $70 billion by 2025. In August 2022, Thermo Fisher Scientific acquired the assets of a leading gene synthesis firm, boosting its capabilities in genetic analysis. Monsanto and Corteva are also expanding their gene editing techniques in agricultural biotechnology, reflecting a growing trend to enhance crop resistance. The US Genetic Engineering Market is marked by innovation and collaboration among major players as they seek to address biotechnology challenges while maintaining regulatory compliance from bodies like the Food and Drug Administration. ## Report Scope | MARKET SIZE 2024 | 268.8(USD Million) | | --- | --- | | MARKET SIZE 2025 | 322.61(USD Million) | | MARKET SIZE 2035 | 2000.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 20.02% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Monsanto (US), Syngenta (CH), Bayer (DE), DuPont (US), Amgen (US), Genentech (US), Regeneron Pharmaceuticals (US), Corteva (US) | | Segments Covered | Product, Devices, Technique, Application | | Key Market Opportunities | Advancements in gene editing technologies drive innovation in agriculture and healthcare within the genetic engineering market. | | Key Market Dynamics | Regulatory advancements and technological innovations drive growth in the genetic engineering market, enhancing competitive dynamics. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation of the US genetic engineering market in 2024?** A: The overall market valuation was 268.8 $ Million in 2024. **Q: What is the projected market valuation for the US genetic engineering market by 2035?** A: The projected valuation for 2035 is 2000.0 $ Million. **Q: What is the expected CAGR for the US genetic engineering market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during the forecast period 2025 - 2035 is 20.02 %. **Q: Which companies are considered key players in the US genetic engineering market?** A: Key players include Monsanto (US), Syngenta (CH), Bayer (DE), DuPont (US), Amgen (US), Genentech (US), Regeneron Pharmaceuticals (US), and Corteva (US). **Q: What are the main product segments in the US genetic engineering market?** A: The main product segments include Biochemical and Genetic Markers, with valuations ranging from 80.0 to 1400.0 $ Million. **Q: What devices are utilized in the US genetic engineering market?** A: Devices such as PCR, Gene Gun, and Gel Assemblies are utilized, with valuations from 60.0 to 950.0 $ Million. **Q: What techniques are prominent in the US genetic engineering market?** A: Prominent techniques include Artificial Selection and Gene Splicing, with valuations from 80.0 to 1400.0 $ Million. **Q: In which applications is genetic engineering primarily used?** A: Genetic engineering is primarily used in Agriculture and the Medical Industry, with valuations from 80.0 to 1360.0 $ Million. **Q: How does the market valuation of the Medical Industry application compare to Agriculture in 2024?** A: In 2024, the Medical Industry application had a valuation of 188.8 $ Million, compared to 80.0 $ Million for Agriculture. **Q: What growth trends are anticipated for the US genetic engineering market in the coming years?** A: The market appears poised for substantial growth, with a projected valuation increase to 2000.0 $ Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-genetic-engineering-market-19372*